DE69132629D1 - Oberflächenkomplexbildung von lymphotoxin - Google Patents

Oberflächenkomplexbildung von lymphotoxin

Info

Publication number
DE69132629D1
DE69132629D1 DE69132629T DE69132629T DE69132629D1 DE 69132629 D1 DE69132629 D1 DE 69132629D1 DE 69132629 T DE69132629 T DE 69132629T DE 69132629 T DE69132629 T DE 69132629T DE 69132629 D1 DE69132629 D1 DE 69132629D1
Authority
DE
Germany
Prior art keywords
beta
lymphotoxin
cell
alpha
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69132629T
Other languages
English (en)
Other versions
DE69132629T2 (de
Inventor
Jeffrey Browning
F Ware
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Biogen MA Inc
Original Assignee
University of California
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Biogen Inc filed Critical University of California
Application granted granted Critical
Publication of DE69132629D1 publication Critical patent/DE69132629D1/de
Publication of DE69132629T2 publication Critical patent/DE69132629T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
DE69132629T 1990-06-27 1991-06-27 Oberflächenkomplexbildung von lymphotoxin Expired - Fee Related DE69132629T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54486290A 1990-06-27 1990-06-27
PCT/US1991/004588 WO1992000329A1 (en) 1990-06-27 1991-06-27 Surface complexed lymphotoxin

Publications (2)

Publication Number Publication Date
DE69132629D1 true DE69132629D1 (de) 2001-07-12
DE69132629T2 DE69132629T2 (de) 2002-04-18

Family

ID=24173910

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69132629T Expired - Fee Related DE69132629T2 (de) 1990-06-27 1991-06-27 Oberflächenkomplexbildung von lymphotoxin

Country Status (11)

Country Link
US (1) US5661004A (de)
EP (1) EP0536299B1 (de)
JP (2) JPH06501456A (de)
AT (1) ATE201879T1 (de)
AU (2) AU8228891A (de)
CA (1) CA2086264C (de)
DE (1) DE69132629T2 (de)
DK (1) DK0536299T3 (de)
ES (1) ES2157889T3 (de)
GR (1) GR3036551T3 (de)
WO (1) WO1992000329A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
CA2142185A1 (en) * 1992-08-10 1994-02-17 David I. Gwynne Inhibitors of cell proliferation, their preparation and use
ATE397665T1 (de) * 1992-12-04 2008-06-15 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
CA2211443A1 (en) * 1995-01-26 1996-08-01 Biogen, Inc. Lymphotoxin-.alpha./.beta. complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6747133B1 (en) 1995-12-08 2004-06-08 University Technologies International Inc. Antibodies against the tumor suppressor gene ING1
US6143522A (en) * 1995-12-08 2000-11-07 University Technologies International, Inc. Methods of modulating apoptosis
US6117633A (en) * 1995-12-08 2000-09-12 University Technologies International Inc. DNA sequence encoding the tumor suppressor gene ING1
US6037121A (en) * 1995-12-08 2000-03-14 University Technologies International Inc. DNA sequence encoding a tumor suppressor gene
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
PT1119370E (pt) 1998-10-09 2006-09-29 Univ Emory Inversao do estado de choque sistemico e de dificuldade respiratoria originado por inducao viral por meio do bloqueio da via da linfotoxina beta
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
CZ20031307A3 (cs) 2000-10-13 2003-10-15 Biogen, Inc. Humanizované protilátky k lymfotoxinovému beta receptoru
EP1539793A4 (de) 2002-07-01 2006-02-01 HUMANISIERTE ANTI-LYMPHOTOIN-BETA-REZEPTOR-ANTIKöRPER
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
NZ550518A (en) 2004-03-23 2009-11-27 Biogen Idec Inc Agents that cross link TNF receptors for treating cancer
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
MX2009003774A (es) * 2006-10-12 2009-04-22 Genentech Inc Anticuerpos para linfotoxina-alfa.
SG154441A1 (en) 2006-10-20 2009-08-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
ES2662845T3 (es) 2007-11-07 2018-04-10 Genentech, Inc. IL-22 para su uso en el tratamiento de trastornos microbianos
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
US10413564B2 (en) * 2016-11-14 2019-09-17 National Yang-Ming University Compositions and methods for combating drug-resistant cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4758549A (en) * 1983-12-13 1988-07-19 Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
CA2001756A1 (en) * 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant

Also Published As

Publication number Publication date
AU2716795A (en) 1996-02-15
US5661004A (en) 1997-08-26
CA2086264A1 (en) 1991-12-28
EP0536299B1 (de) 2001-06-06
DK0536299T3 (da) 2001-07-09
JPH06501456A (ja) 1994-02-17
EP0536299A1 (de) 1993-04-14
ATE201879T1 (de) 2001-06-15
ES2157889T3 (es) 2001-09-01
GR3036551T3 (en) 2001-12-31
JP2004002461A (ja) 2004-01-08
AU8228891A (en) 1992-01-23
DE69132629T2 (de) 2002-04-18
WO1992000329A1 (en) 1992-01-09
JP4099119B2 (ja) 2008-06-11
AU688056B2 (en) 1998-03-05
CA2086264C (en) 2002-12-24

Similar Documents

Publication Publication Date Title
DE69132629D1 (de) Oberflächenkomplexbildung von lymphotoxin
HK1013835A1 (en) Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preperations and therapeutic uses thereof
Lundin Evolution of the vertebrate genome as reflected in paralogous chromosomal regions in man and the house mouse
ES8308361A1 (es) Un metodo para la produccion de un polipeptido.
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
KR900700592A (ko) 용해성 티-4 유도체
Pryor Allelic glutamic dehydrogenase isozymes in maize—a single hybrid isozyme in heterozygotes?
Misra et al. Lymphocyte plasma membranes II. Cytochemical localization of 5′-nucleotidase in rat lymphocytes
Shearer et al. Regulation of cell growth by interferon
DE69809561T2 (de) Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod
Kay et al. Ornithine decarboxylase in phytohaemagglutinin stimulated lymphocytes: Control of degradation rate by amino acids
Weiland et al. Differences in the in vitro response of lymphocytes from leukotic and normal cattle to concanavalin A
Glazer et al. Appearance of membrane-bound tyrosine kinase during differentiation of HL-60 leukemia cells by immune interferon and tumor necrosis factor
SE8605459D0 (sv) Novel cell growth regulatory factor
EP0336383A3 (de) Menschliches rekombinantes Lymphotoxin
Miyazaki et al. Characterization of a growth-inhibiting protein present in rat serum that exerts a differential effect on in vitro growth of nonmalignant rat liver cells when compared with Rous sarcoma virus-transformed rat liver cells
Cederbaum et al. Glucose 6-phosphate dehydrogenase in rainbow trout
CA2051085A1 (en) Expression plasmids
Lewis Polymorphism of human enzyme proteins
Valentine et al. Augmentation of interleukin-2 release by cytochalasins
Maclean et al. Studies on the template activity of ‘isolated’Xenopus erythrocyte nuclei: II. the effects of cytoplasmic extracts
Wegier-Filipiuk et al. Activity of aminoacids incorporating systems isolated from liver and kidney of rat intoxicated with thiuram.
Erickson Genetic control of glutamate oxaloacetic transaminase in murine spermatozoa
Heidemann Humoral factors in the regulation of cell proliferation in haematopoiesis: I. Granulopoiesis and lymphopoiesis
Bertoglio et al. The reactivity of frozen B lymphocytes to B cell mitogens and human B cell growth factor: A study of step 1 and step 2 activators

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OAKLA

8339 Ceased/non-payment of the annual fee